Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $28.00.

XNCR has been the subject of several research reports. William Blair initiated coverage on Xencor in a research report on Monday, April 21st. They issued an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Finally, Barclays reduced their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th.

Xencor Price Performance

Shares of NASDAQ:XNCR opened at $9.24 on Monday. The firm has a market capitalization of $657.61 million, a PE ratio of -3.02 and a beta of 0.85. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The business’s 50 day moving average is $8.60 and its 200-day moving average is $11.70. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.16.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The firm had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The firm’s revenue for the quarter was up 104.6% compared to the same quarter last year. During the same period last year, the business earned ($1.11) earnings per share. Sell-side analysts predict that Xencor will post -3.68 earnings per share for the current year.

Insider Buying and Selling

In other Xencor news, Director Kurt A. Gustafson sold 2,993 shares of Xencor stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director owned 20,183 shares in the company, valued at approximately $186,087.26. The trade was a 12.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard J. Ranieri sold 2,993 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. This represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,810 shares of company stock valued at $154,123. 5.23% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its position in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Xencor during the 4th quarter worth about $34,000. State of Wyoming acquired a new position in Xencor during the 1st quarter worth about $34,000. CWM LLC lifted its position in Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 2,231 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in Xencor during the 1st quarter worth about $56,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.